50 results about "Biomarker Analysis" patented technology

The invention relates to the technical field of cardiovascular medicine, in particular to an automatic alarm system for cardiovascular medicine, which comprises a biomarker analysis module, a physiological parameter analysis module, a cardiovascular risk assessment module, a cardiovascular early warning adjustment module and an alarm trigger notification module. According to the invention, by integrating real-time monitoring of blood biomarkers and cardiovascular physiological parameters, the early recognition capability of cardiovascular disease risks is improved, key biomarkers are dynamically measured and compared with historical marker data, and subtle physiological changes can be captured at the early stage of asymptomatic conditions, so that potential cardiovascular events are warned; through correlation analysis of electrocardiogram, blood pressure and pulse waveforms, the system can accurately draw a comprehensive image of cardiovascular functions, so that more targeted monitoring and intervention are implemented, timeliness and accuracy of medical response are ensured, doctors can formulate targeted monitoring schemes according to real-time data, and the monitoring efficiency is improved. Therefore, deterioration or occurrence of cardiovascular events of patients can be effectively prevented.

The present disclosure provides a method for biomarker analysis. More particularly, provided herein is a method for identifying biomarker(s) associated with mental health disorder(s) such as but not limited to Major Depressive Disorder (MDD). The said method of the present disclosure is based on an integrative analysis between machine learning and bioinformatics techniques. The method allows efficient mining of publicly available datasets pertaining to mental health disorder patients to identify biomarkers that can aid in the diagnosis and prediction of the onset of such mental health disorders. Further envisaged herein are the biomarker(s) identified by the said method which allow early and efficient detection of mental health disorder(s) by non-invasive methods and application(s) of such biomarker(s).

The invention discloses a biomarker for nephrotic syndrome, an analysis method and a kit, which can be effectively used for diagnosis of nephrotic syndrome and have high sensitivity and accurate and reliable results. The biomarker for nephrotic syndrome comprises the mRNA, the protein and the enzymatic activity level of the following substances: lactate dehydrogenase B.

A wearable biosensor for real-time quantification of a biomarker in a biofluid includes at least one functional module. The functional module includes an iontophoresis induction module, a microfluidic layer, a plurality of multimodal biosensors, and a paperfluidic layer.

The invention discloses a dynamic biomarker analysis method and system based on big data, and relates to the technical field of data analys.The dynamic biomarker analysis method comprises the steps of obtaining dynamic biomarker data, obtaining a batch effect removing method corresponding to each dynamic biomarker data according to the dynamic biomarker data, and obtaining a batch effect removing method corresponding to each dynamic biomarker data based on the batch effect removing method; and processing the dynamic biomarker data to obtain biomarker processing data. According to the method, the data comparability is ensured and the reliability of subsequent analysis is improved through a data attribute intelligent matching batch removal effect method, the batch removal effect is verified through the differential gene number and the overlapping rate, the stability of the data is ensured, the biomarker data types related to the target disease are selected through the biomarker feature set, and the accuracy of the biomarker data types related to the target disease is improved. According to the method, the data calculation amount is reduced, the data analysis efficiency is improved, and a more comprehensive risk assessment basis is provided for clinic by constructing the regulation and control network containing the molecular interaction relationship.

The invention discloses an ankylosing spondylitis prediction model construction method based on a neural network, and belongs to the technical field of biomedicine, and the method specifically comprises the following steps: sample collection: collecting a blood sample; preparing a sample; performing mass spectrum identification: performing mass spectrum analysis by adopting a Linear mode of a mass spectrometer; performing data analysis; performing MS file processing; performing mass spectrum detection on peak profile data, and setting a threshold value as Plt; 0.01 and log2 (FC) gt; 1, screening a differential mass spectrum peak; carrying out LASSO dimension reduction on the differential mass spectrum peaks to screen mass spectrum characteristic peaks; analyzing the identification efficiency of the mass spectrum characteristic peak on the ankylosing spondylitis by an ROC method; carrying out artificial neural network algorithm modeling; and analyzing and predicting the data of the test set by using the artificial neural network model. More detailed and comprehensive biomarker analysis can be provided, and the overall metabolic state and the pathological process of a patient and good medication curative effect evaluation can be reflected.

The invention related to a method for selective enrichment of glycoproteins from a sample comprising proteins, the method comprising: —determining the concentration of proteins in the sample or providing the sample with a defined concentration of proteins; incubating particles in the sample to form a protein corona comprising glycoproteins bound to the surface of the particles, wherein the protein concentration to the total surface area of the particles is selected, and / or the particle material is selected, in order to enrich for a specific glycoprotein species on the protein corona; and optionally isolating the protein corona from the sample; and associated methods of screening for biomarkers and diagnosis, and associated compositions.

We provide specimen analyzers, specimen analysis systems, specimen analysis methods, and programs that can contribute to highly accurate dementia diagnosis using dementia biomarkers. [Solution] The specimen analyzer 1 comprises a measuring device 2 that measures analytes related to dementia biomarkers contained in a specimen taken from a subject, a storage unit that stores reference values ​​for identifying outliers that may occur due to factors other than dementia, a control unit that determines whether the measured value is identified as an outlier based on the measured value of the analyte by the measuring device 2 and the reference value, and generates biomarker analysis results according to the result of the determination, and an output unit that outputs the biomarker analysis results.

The invention relates to the technical field of medical care, in particular to a polycystic ovarian syndrome detection method based on multi-dimensional biomarker analysis, which comprises the following steps: S1, patient data acquisition: acquiring multi-modal health data of a patient; s2, integrating and standardizing the biomarker data: integrating the health data of different dimensions; s3, performing pathogenesis inference based on a hormone and metabolism coupling model: performing coupling analysis on the hormone level and metabolism data of the patient, and revealing a mutual influence mechanism of the hormone level and the metabolism data in the polycystic ovarian syndrome; s4, risk score calculation: calculating the risk score of the polycystic ovarian syndrome of the patient; and S5, diagnosis feedback and dynamic optimization: dynamically adjusting the detection scheme. According to the method, the accuracy and the flexibility of the diagnosis and treatment scheme are improved, all-around data support is provided for doctors, and personalized and dynamic long-term health management and optimization of the treatment scheme are assisted.

The invention relates to the technical field of medical care, and discloses a heart failure patient noninvasive liquid management nursing system which comprises a data acquisition module used for acquiring biomarkers of a heart failure patient and analyzing a body fluid state change rule of the heart failure patient; the body fluid state monitoring module is used for measuring impedance values of different parts of the heart failure patient and analyzing the evolution trend of the retention condition of the liquid retention part; the risk state identification module is used for analyzing the heart failure severity of the heart failure patient; the risk control module is used for generating illness condition guidance suggestions of the heart failure patient, constructing a risk early warning mechanism of the heart failure patient and creating a health management system of the heart failure patient; and the liquid management module is used for analyzing the liquid management effect of the heart failure patient in combination with a health management system, illness condition guidance suggestions and a risk early warning mechanism so as to execute liquid management processing of the heart failure patient and obtain a liquid management result. The pertinence and effectiveness of liquid management nursing of the heart failure patient can be improved.

The invention provides an S100B and NSE double-signal electrochemical immunosensor, a preparation method, application and a detection product, and belongs to the technical field of electrochemical detection. According to the preparation method, the PAMAM dendritic polymer rich in amine-terminated functional groups is covalently grafted to the MXene conductive sheet layer with a large surface area to prepare the PAMAM-MXene composite material, so that the immobilization efficiency and interface electron transfer of immune molecules are remarkably improved through modification, and enhanced conductivity and relatively high specific surface area are shown; and the biomolecule loading capacity and the signal transmission efficiency of the electrode are also remarkably improved, and double-signal detection can be performed on S100B and NSE at the same time. And the electrochemical immunosensor has good reproducibility, long-term stability and anti-interference capability on the two biomarkers. According to the sensor, modular design and signal decoupling are adopted, double targets can be accurately detected in parallel, and an extensible strategy is provided for multiplexing biomarker analysis.

A device (1) whose body (2) due to its convex design (5) makes it anatomical with the palm of the hand of the target individual, who will place it on a collection adapter (10) with medium-sized hollow (12), conducive to the concentration of blood without interrupting the blood flow, which will be submitted for analysis of biomarkers performed in the chamber (9) of the optical system inside the body (2).

A wearable smart ring includes an annular body sized to receive a finger, photoplethysmography (PPG) sensors arranged along an inner peripheral surface, and a microfluidic perspiration collector disposed at the inner surface. The collector has microchannels that draw perspiration by capillary action into one or more reservoirs and includes a region that concentrates or retains biomarkers. A docking station mechanically receives the ring for charging and interfaces with the collector to transfer fluid and / or perform in-situ analysis. The dock includes optical instrumentation (e.g., photometry, spectroscopy such as Raman) and may implement pumping and flushing to reset the collector for subsequent use. A controller communicates results by wireless links. The system enables passive collection of perspiration during wear and detailed biomarker analysis during charging, thereby augmenting PPG-derived physiological measurements with perspiration chemistry without burdening ring power or size.

The present invention relates to the field of biological data processing, and discloses a lung cancer immune marker analysis method, device, electronic device and storage medium, wherein the method comprises: using fluorescent signal amplification technology to perform a multi-biomarker staining operation on lung tumor tissue to obtain a tissue staining image set; performing real cell selection on the tissue staining image set according to the region of interest input by the user to obtain a circled image set; performing quantitative statistics on each biomarker in the circled image set according to a preset optimal positive threshold screening strategy to obtain the tissue marker positive rate, interstitial marker positive rate and double positive rate between target biomarkers corresponding to each biomarker; and outputting the tissue marker positive rate, interstitial marker positive rate and double positive rate in a structured manner to obtain lung immune marker positive data. The main purpose of the present invention is to improve the comprehensiveness and accuracy of biomarker analysis of the lung cancer immune microenvironment.

Provided herein are methods and systems for detection and monitoring of cancer. The method may comprise use of multiple biomarkers, such as fragmentomics, methylation, and gene expression, or transcription factor activation. The methods and systems may comprise using nucleic acids to generate a fragmentomics profile (e.g., nucleosome profile). The methods and systems may comprise assaying nucleic acids to detect expression of genes of a subject.

The biomarker, the analysis method and the application can be effectively used for early diagnosis, disease course monitoring and prognosis evaluation of asthma, are high in sensitivity, rapid, convenient and accurate and reliable in result, can be used for multiple times of monitoring in a clinical control period, a chronic duration period and an acute attack period of an asthma patient, and provide a basis for clinical decision making. Meanwhile, a certain basis is provided for subsequent fundamental research and clinical research, and the method has great application and research values.

Immunohistochemistry (INC) and in situ hybridization (ISH) methods are used for the targeted detection and localization of biomolecules (e.g., proteins and miRNAs) in tissues or cells, for research applications and clinical applications such as those of pathologists (e.g., biomarker analysis of resected tumors or tumor biopsies). These methods include mass spectrometry imaging (MSI) as a mode for detecting and localizing biomolecules in tissues or cells. The methods employ optically cleavable mass-tagged reagents linked to probes such as antibodies and nucleic acids and used to enable multiplexed immunohistochemistry and in situ hybridization, with MSI as the detection / readout mode. The methods also include multi-omics MSI procedures in which MSI of optically cleavable mass-tagged probes is combined with other MSI modes, such as direct label-free MSI of endogenous biomolecules from biological samples (e.g., tissues).

The invention discloses a biomarker, an analysis method and application, can be effectively used for disease course monitoring and prognosis evaluation of chronic obstructive pulmonary disease, is high in sensitivity, rapid and convenient, and accurate and reliable in result, can be used for monitoring patients with mild, moderate, severe and extremely severe chronic obstructive pulmonary disease for multiple times in a stable phase and an acute exacerbation phase, and provides a basis for clinical decision making. Meanwhile, a certain basis is provided for subsequent fundamental research and clinical research, and the method has great application and research values.

Disclosed are miniaturized electronic systems, devices and methods for biomarker analysis, which can be incorporated into blood collection tubes and other containers that enable the immediate isolation, concentration, analysis and storage of disease related biomarkers upon blood draw. In some aspects, a miniaturized electronic system includes a high-surface area folded or sandwiched electrokinetic microelectrode array chip device that allows both AC dielectrophoretic (DEP) and DC electrophoretic based separation and isolation and other processes to be used for the concentration and biomarkers.

The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection / readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).

Disclosed are novel RNA and protein expression panels and methods of using said panels for the detection of cancer and determining the suitability of a subject for a treatment regimen or clinical trial.

A tape (170) comprising: a base membrane (410) on which dry rods (180a, 180b, 180c) are separately arranged, the dry rods (180a, 180b, 180c) being configured to indicate at least one biomarker value of a milk sample of an animal (100); and a top film (310) configured to cover the plurality of stem rods (180a, 180b, 180c) disposed on the base film (410) and to peel from individual stem rods (180a, 180b, 180c) prior to applying a milk sample to the stem rods (180a, 180b, 180c).

The invention discloses a method for detecting a soil microbial marker-amino sugar by direct ion chromatography, and relates to the technical field of biomarker analysis, and the method comprises the following steps: adding a soil sample into a 6mol / L hydrochloric acid solution, and hydrolyzing at 105 DEG C for 8 hours; drying the hydrolysate with nitrogen, redissolving with ultrapure water, centrifuging, taking supernate, and filtering with a 0.22 mu m filter membrane to obtain a to-be-detected solution; the method comprises the following steps: injecting a to-be-detected solution into an ion chromatography system provided with an electrochemical detector, and carrying out gradient elution by adopting an anion exchange chromatographic column and taking a mixed solution of sodium hydroxide and sodium acetate as a mobile phase to realize separation and quantitative detection of glucosamine (GlcN), galactosamine (GalN), aminomannose (ManN) and muramic acid (Mur). A highly toxic derivatization step necessary for a traditional method is omitted, a sample can be directly injected through three-step purification after acid hydrolysis, and efficient separation of four amino sugars is realized by matching with a special ion chromatography system.

The invention discloses a carrier for acquiring life information and a method for applying the carrier, and belongs to the technical field of biomedicine. The method solves the problem that a required sample is difficult to quickly obtain during practical application of an existing method, realizes accurate extraction and detection of a life information carrier by integrating a magnetic bead separation technology and fluorescent quantitative detection, and performs intelligent classified storage and dynamic management based on data volume and data type, so that the life information carrier can be accurately extracted and detected during practical application. According to the method, quick retrieval and application can be performed in the specified storage area according to the data volume of the life information required to be applied, so that the management efficiency and retrieval speed of the life information are remarkably improved; the system can realize rapid biomarker analysis in disease diagnosis, supports dynamic data tracking in treatment monitoring, promotes accurate scheme formulation in personalized medical treatment, and achieves the comprehensive effects of improving medical detection efficiency, reducing storage cost and enhancing clinical application flexibility.

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.

Systems and methods are provided for improving skincare product formulations to address predicted skin trends. A biomarker analysis system is used to determine concentrations of various protein biomarkers of a user. A skin diagnosis computing device uses the protein biomarker concentrations to determine one or more skin trends, and determines one or more skincare product ingredients to address the skin trends. A skincare product is compounded that includes the one or more skincare product ingredients.

The invention relates to the technical field of tumor cell drug resistance detection, and discloses a construction method and application of a tumor cell drug resistance level detection model based on surface enhanced Raman scattering. The invention particularly provides a tumor cell drug resistance level detection method based on surface enhanced Raman scattering and machine learning (recursive feature elimination-radial basis function-support vector machine), the mixing ratio of silver nanoparticles (70-80 nm, 9-10 mM) enhanced substrate to cell homogenate (1: 2-1: 4) is optimized, Raman spectrum feature extraction and nonlinear modeling are combined, and the drug resistance level of tumor cells is detected. The accurate quantitative detection of the drug resistance index (1-15 times) is quickly realized. Compared with traditional drug sensitive experiments and biomarker analysis, the method has the advantages of high efficiency, high sensitivity, strong anti-interference performance and the like, effectively solves the clinical problems of long period, complex operation and incapability of dynamically monitoring the drug resistance level in the prior art, and provides an efficient and reliable detection tool for personalized treatment of tumors.

The present invention belongs to the field of bioengineering technology, and specifically relates to a biomarker detection method and application based on photoexcitation electrically driven reactive oxygen channels. The present invention first provides a detection system for photoexcitation electrically driven reactive oxygen channels, which mainly includes a reaction module, a photoexcitation module, an electric drive module and an reactive oxygen channel reaction reagent. The reactive oxygen channel reaction reagent includes a donor bead complex containing a photosensitizer and an acceptor bead complex containing polyphenols, and the donor bead complex includes a metal organic framework containing a photosensitizer coupled with a first reactant; the acceptor bead complex includes melanin-like nanoparticles containing polyphenols coupled with a second reactant; the first reactant and the second reactant are configured to connect or identify a target substance in a biological sample to be detected to form a donor bead-acceptor bead connector. Using the detection device provided by the present invention to perform biological sample detection, a "wash-free and separation-free" homogeneous biomarker analysis can be achieved, with high sensitivity and strong anti-interference ability.

Systems, devices, and methods for skin biomarker analysis and computation of predicted responsiveness to skincare treatments for management of skin health. A system is configured to receive a measurement of one or more skin biomarkers, compute a predicted beauty outcome that is predicted to occur due to a course of action, and recommend or not recommend the course of action, based on the responsiveness metric, such that the skin health of the individual is advanced toward a desired beauty outcome. Systems can recommend products, services, and other courses of action such as lifestyle changes, to improve the health of the individual.

The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection / readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).